Back to search

Article

A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway

2020-11-24

Abstract excerpt

<h4>Background: </h4> Anti-angiogenic therapy has been widely applied to the clinical treatment of malignant tumors. However, the efficacy of such treatments has been called into question, especially in triple-negative breast cancer (TNBC). Bevacizumab, the first anti-angiogenic agent approved by FDA, actually increases invasive and metastatic properties of TNBC cells, resulting from the activation of Wnt/β-cateni...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
70c0eff8-b641-57b2-8d7c-9919b2aa1e53
DOI
10.21203/rs.3.rs-66233/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathwayDOI 10.21203/rs.3.rs-66233/v2
Select a neighboring publication to make it the new centre.